Background-Genetic studies in mouse and human suggest that kynureninase activity may influence blood pressure and renal function. The gene coding kynureninase (KYNU) is also located on chromosome band 2q14-q23, where a linkage peak for essential hypertension was previously detected in the Chinese Han population. Methods and Results-After having found no association with common polymorphisms, this study aimed to assess the role of 1 rare variant of KYNU, Arg188Gln, and kynureninase activity in relation to hypertension. Thirty-three of 1124 Chinese patients with hypertension were heterozygous for Arg188Gln, whereas only 14 of 1084 normotensive controls were heterozygous for Arg188Gln (188G1n allele frequency, 0.015 versus 0.006; Pϭ0.0075). A genotype-discordant sibling-pair study was performed in another 924 individuals from 213 families, indicating that 188G1n carriers had higher systolic blood pressure (168.29Ϯ24.67 versus 139.00Ϯ12.82 mm Hg, PϽ0.001) and diastolic blood pressure (105.50Ϯ14.08 versus 90.75Ϯ11.07 mm Hg, Pϭ0.001) than did Arg188 homozygous siblings. The Arg188Gln variant was found to be rarer in 2 other ethnic groups (3 heterozygous among 880 hypertensive French whites and 0 of 90 black Africans with hypertension). The kynureninase activity in plasma was correlated with blood pressure in subjects from hypertensive families (PϽ0.05). The Kinetic Michaelis constants of 188Gln carriers was lower than that of Arg188 homozygous subjects (0.05Ϯ0.02 versus 0.10Ϯ0.02 mmol/L, Pϭ0.005). Arg188Gln mutation in vitro also showed less catalytic efficiency than the wild-type KYNU enzyme (maximal reaction velocity/Kinetic Michaelis constant ratio, 0.050Ϯ0.012 versus 0.11Ϯ0.016 mL/min per mg; Pϭ0.029). Conclusions-The results show that the rare KYNU variant Arg188Gln affects kynureninase activity and are consistent with the hypothesis that this mutation can predispose to essential hypertension. (Circ Cardiovasc Genet. 2011;4:687-694.)
K ynureninase is a pyridoxal-5Ј-phosphate (PLP)dependent constitutive enzyme involved in the kynurenine pathway of the biosynthesis of nicotinamide adenosine dinucleotide cofactors from tryptophan. 1, 2 Tryptophan is transformed into kynurenine in a reaction catalyzed by indoleamine 2,3-dioxygenase and tryptophan 2,3-dioxygenase. Kynurenine is then converted to kynurenic acid, 3-hydroxykynurenine, and anthranilic acid by kynurenine aminotransferase, kynurenine 3-hydroxylase, and kynureninase, respectively. In humans, the kynureninase gene (KYNU) is cloned and localized to chromosome 2q22.1. 3 The kynurenine pathway is the main metabolic pathway for tryptophan and has been associated with neurological diseases and mental disorders, including Alzheimer disease, Huntington disease, schizophrenia, anxiety, and depression. 4 -8 It has been reported that injection of kynurenic acid into the rostral ventrolateral medulla of spontaneously hypertensive rats decreases arterial blood pressure (BP) 9 and that KYNU polymorphisms cosegregate with hypertension in the spontaneously hypertensive rat and Wistar Kyoto cross-rat strain. 10 Relationships also have been described between plasma kynurenine and catecholamines and hypertension. 11 Recently, kynurenines were further found to be associated with the markers of kidney function. 12 Little is known, however, about its possible links with human hypertension.
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Linkage studies have mapped several BP susceptibility and hypertension loci to chromosome 2. [13] [14] [15] Using 3-stage genome-wide scanning, an essential hypertension susceptibility locus has been mapped to 2q14-q23 (D2S112-D2S2370) in Chinese patients 16 within several single-nucleotide polymorphisms (SNPs) observed to be associated with hypertension in Chinese case-control association studies. 17, 18 A recent genome-wide association study (GWAS) of a genetically isolated population has also identified an additional hypertension susceptibility gene, STK39, on chromosome 2q24.3. 19 These findings suggest allelic heterogeneity of the candidate region where KYNU is located. To our knowledge, common polymorphisms around KYNU were not reported to be associated with hypertension or BP from recent GWASs.
In the present study, we first excluded the role of common variants near KYNU. Then we searched and evaluated 1 low-frequency missense variant, Arg188Gln (G/A), in relation to essential hypertension among Chinese, using data from a population-based case-control study and a genotypediscordant sibling-pair study from hypertensive families. This variant was also functionally characterized by in vitro and in vivo experiments. We tested the frequency of this rare variant in hypertensive French whites and black Africans.
Methods

Study Populations
In the case-control association study, we recruited 1124 unrelated Chinese patients with hypertension and 1084 age-and sex-matched unrelated healthy controls. In the genotype-discordant sibling-pair study, we recruited 924 individuals from 213 families, which were designated by a hypertensive proband investigated in the specialized hypertension clinic of the Shanghai Ruijin Hospital. All available siblings in the selected families were invited to take part in this study. We also used an independent case-control cohort recruited for an ongoing GWAS, which was included in the GWAS meta-analysis of BPs in East Asians. 20 All these individuals were of Han Chinese origin and from the Shanghai area. The Ethics Committee of the Ruijin Hospital, Shanghai Jiaotong University School of Medicine, approved the study protocol, and all participants gave written informed consent.
Experienced nurses or technicians measured BP, body height, and weight. BP was measured 3 times after a 10-minute rest in the sitting position using a mercury sphygmomanometer. One 10-mL blood sample was drawn from all subjects for DNA extraction and biochemical examination. All biochemical measurements, including plasma fasting glucose and serum concentrations of total cholesterol, triglycerides, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, urea nitrogen, creatinine, and uric acid, were performed in the central laboratory of Ruijin Hospital, using standard protocols.
Hypertension was defined as an average systolic blood pressure (SBP) Ն140 mm Hg, an average diastolic blood pressure (DBP) Ն90 mm Hg, and self-reported current treatment for hypertension with antihypertensive medications. To correct for treatment effects on the BP measure, 10 and 5 mm Hg were added to SBP and DBP, respectively, for patients who took antihypertensive drugs. Body mass index (BMI) was defined as weight in kilograms divided by the square of height in meters. Individuals with valvular heart disease, congenital malformations of the heart or blood vessels, or renal or endocrinopathies that cause secondary hypertension were excluded from the study. The control subjects had an SBP Ͻ140 mm Hg and a DBP Ͻ90 mm Hg and were not taking any antihypertensive medications.
To evaluate the association of common SNPs near KYNU with phenotypes of interest, we used our GWAS data of essential hypertension in Han Chinese. We adopted stringent criteria for case-control selection in our GWAS sample. In addition to the previous case definition, we required subjects to have (1) an age of onset between 30 and 60 years, (2) at least 3 hypertensive family members, (3) a fasting glucose Ͻ6.1 mmol/L and no family members with diabetes, and (4) a BMI Ͻ25 kg/m 2 . Controls were required to have (1) an SBP Ͻ120 mm Hg and a DBP Ͻ80 mm Hg, (2) an age of Ͼ40 years, (3) a BMI Ͻ25 kg/m 2 , and (4) a fasting glucose Ͻ6.1 mmol/L. GWAS data quality control procedures are described briefly in the online-only Data Supplement. A total of 902 quality control-passed samples were used in this analysis, including 447 hypertensive cases (224 male and 223 female) and 455 controls (230 male and 225 female). Phenotype summary data for the study cohort are provided in online-only Data Supplement Table II . We also genotyped 880 French white hypertensive probands of the Hypergene cohort 21 and 90 hypertensive black Africans recruited in Paris, France.
SNP Detection and Genotyping
To discover additional variants of functional relevance, we sequenced the 2-kb promoter region located upstream from the first exon, all exons, and flanking intronic sequences and 1-kb downstream from 3Ј using an ABI 377 Automatic Sequencer (Applied Biosystems). Polymerase chain reaction primers were designed using the software program Primer 3 (online-only Data Supplement Table I ). Genotyping of the selected SNP in Chinese Han population, French white, and black Africans was performed using the ABI TaqMan method (Applied Biosystems). All the minor allele carriers were further confirmed by direct DNA sequencing. The GWAS cohort was genotyped using Illumina HumanHap 610k-Quad BeadChips.
Assay for Human Kynureninase Activity
Twenty-four blood samples from 6 hypertensive families having Ͼ2 Arg188Gln (GϾA) A allele carriers in the genotype-discordant sibling-pair cohort were collected for kynureninase activity measurement. All the subjects had no history of taking vitamins and were asked not to take any drugs for at least 2 weeks and food for at least 12 hours before the measurement. The lymphocytes were isolated from peripheral blood collected, using heparin as an anticoagulant. Kynureninase activity was measured according to a previously published method 22 by high-performance liquid chromatography (Agilent 1100; Agilent Technologies). Kinetic Michaelis constants (Km) and maximal reaction velocity (Vmax) were calculated using the Michaelis-Menten equation. The intraassay precision was estimated from the 5 replicates of pooled samples at 3 different concentrations (low, medium, and high) based on the standard curve, ranging from 0.2% to 3.0% (coefficient of variance). The interassay precision is similarly evaluated over a 5-day period, ranging from 0.7% to 3.2%. The variability between duplicates was much lower than the 12% limit recommended by the manufacturer.
Mutagenesis of Arg188Gln and Lys412Glu
Plasmids Human kynureninase was amplified by polymerase chain reaction from a liver cDNA bank using 2 specific primer sequences (sense, CCGCTCGAGATGGAGCCTTCATCTCTTGAG; antisense, CGCGGATCCCGATTTTTTGTTTCTGCAGAGTC), and the resulting 1398-bp fragment, ranging from transcriptional start site to stop codon, was inserted into the XhoI and BamH I site of eukaryotic expression vector pEGFP-N1 (Clontech; Takara Bio). Mutant human kynureninase cDNA was generated by site-directed mutagenesis.
Mutant primer sequences with the mutated base underlined were as follows: Arg188Gln Arg188Gln (primer1 AGAAAGTATGCA-GATGATAAAG; primer2 TTATCATCTGCATACTTTCTTC); Lys412Glu (prime1 GAAAACATCTTCGTTTGGAACAG; primer2 CTGTTCCAAACGAAGATGTTTTC). The resulting plasmid was sequenced to confirm the identity as the Genbank cDNA sequence.
Expression of Recombinant Human Wild-Type and Mutant Kynureninase in Human Embryonic Kidney 293 Cells and Enzymatic Activity
Human recombinant wild-type and mutant kynureninase cDNAs were transiently transfected into human embryonic kidney 293 (HEK293) cells using Lipofectamine 2000 (Invitrogen) according to the manufacturer's instructions. The cells were harvested 48 hours after transfection by adding ice-cold sodium 5,5-diethylbarbiturate-HCL buffer (pH 8.4) and 1% Triton X-100 solution. After sonication, the homogenate was centrifuged (13 000 rpm for 30 minutes), and the supernatant was stored at Ϫ80°C. Kynureninase activity was measured according to a previously published method. 22 To further confirm the results, we transfected recombinant KYNU into HEK293 cell lines followed by G418 selection. Stable G418resistant colonies were obtained for more measurement of the enzyme activity.
Statistical Analysis
SPSS version 12.0 (SPSS Inc) was used for phenotype data management and analysis. All clinical data were presented as meanϮSD or meanϮSE within each group. Comparison of allele frequency between cases and controls or among ethnic groups was achieved through the 2 or Fisher exact test; differences between means were tested by t test or ANOVA. A PϽ0.05 was considered a significant difference between 2 classes. The relationship between kynureninase activity and BP level was tested using the Pearson correlation analysis. Data from the genotype-discordant sibling-pair study were analyzed using a permutation test for paired replicates. In brief, phenotypes within each pair were randomly assigned to individuals, and empirical null distribution was estimated from a large (10 7 ) random sample. If the observed sum of differences entered into the 5% region of rejection, the difference between pairs was considered significant.
For the unrelated case-control cohorts, association testing with hypertension status was performed using a logistic regression model that allowed us to include important covariates such as sex, age, age 2 , and BMI. In the common SNP association analysis, haplotype association tests were also used. The haplotype association analysis was conducted using a 2-step procedure. First, the most likely haplotypes for each individual were inferred from case-control combined genotypes using beagle. 23 We then fitted the inferred haplotypes using a graphical model that accounts for the linkage disequilibrium structures of nearby SNPs, where each edge represents a localized haplotype cluster. 24 The localized haplotype clusters were then converted to pseudo-biallelic markers and tested for association with hypertension using the regression models.
Results
Investigation of Common SNPs With Essential Hypertension
To evaluate the association of common SNPs and essential hypertension, we extracted the KYNU region (defined as 50 kb upstream to 20 kb downstream of KYNU) (Figure 1 ) from the GWAS SNP data. The whole-genome data were subject to rigorous quality control procedures so that the impact of technical artifacts and population stratification was minimal. There were 49 SNPs within the targeted candidate region that passed quality control on the Illumina 610k-Quad BeadChip. They captured 89.7% (156/174) of common SNPs (minor allele frequency, Ͼ0.05) in the HapMap JPTϩCHB (Japanese in Tokyo and Han Chinese) panel at linkage disequilibrium r 2 Ͼ0.8, and almost all (173/174) common SNPs at linkage disequilibrium r 2 Ͼ0.5. Thus, markers on the Illumina platform provided ideal coverage for the common SNPs in this region. Using a spectral decomposition method, we estimated that they amounted to 43 independent markers, 25 so the experiment-wise significance threshold of single marker tests should be 1.1e-3 to keep the false-positive rate Ͻ5%. The real threshold should be more stringent because we performed the statistical tests using both single markers and haplotype clusters. No single SNP or haplotype survived multiple test correction.
Detection of Rare Variants
Given the absence of association between common SNPs and hypertension, we next set out to discover rare variants in the coding regions of KYNU. DNA samples of 96 random unrelated subjects from the study population were used for SNP detection in KYNU. Two missense SNPs, rs2304705 and rs9013, were validated in the Han Chinese population. One of the nonsynonymous cSNPs, rs9013 (AϾG, Lys412Glu), was already typed on the Illumina platform and found to be not associated with hypertension and adjusted BPs (PϾ0.2). The other cSNP, rs2304705 (GϾA) leading to a substitution from arginine to glutamine at codon 188 (Arg188Gln), was observed only once in the discovery cohort.
Association Studies of Arg188Gln With Hypertension and Phenotypes
The low-frequency Arg188Gln was then genotyped in 1124 unrelated Chinese patients with hypertension and 1084 unrelated Chinese normotensive controls. The observed genotype frequency was in Hardy-Weinberg equilibrium, with PϾ0.05 both in hypertensive cases and in normotensive controls. Thirty-three patients with hypertension and 14 normotensive controls were heterozygous for Arg188Gln. There was an association between hypertension and Arg188Gln (GϾA). The frequency of the A allele (0.015 versus 0.006; odds ratio, 2.29; 95% CI, 1.19 -4.64; Pϭ0.0081) and the GA genotype (odds ratio, 2.31; 95% CI, 1.20 -4.70; Pϭ0.0078) was significantly higher in the patients with hypertension than in controls ( Table 1 ). The association remained significant after adjusting the effects of sex, age, and age 2 in the logistic regression (odds ratio, 2.30; 95% CI, 1.22-4.36; Pϭ0.01). We further included 1 or all of the covariates that showed significant differences between cases and controls with no more than 25% missing data; the results were quantitatively similar (PϽ0.01). Among the Arg188Gln heterozygotes, 32 of 33 (96.97%) patients with hypertension and 7 of 14 (50%) controls reported a family history of hypertension. We also found that subjects with the GA genotype had higher mean levels of SBP, DBP, mean arterial pressure (MAP), and serum creatinine than subjects with the GG genotype ( Table  2) . The difference for serum creatinine remained significant after adjustment for age, sex, BMI, MAP, and antihypertensive medications (83.38Ϯ2.15 versus 76.93Ϯ0.36, Pϭ0.003).
Genotype-Discordant Sibling-Pair Study for Rare Polymorphism Arg188Gln
A genotype-discordant sibling-pair study was performed for this low-frequency polymorphism. A total of 924 individuals from 213 families were genotyped (online-only Data Supplement Table III ). Among them, we found 24 genotypediscordant sibling-pairs for this variant (24 GG homozygotes, 21 GA heterozygotes, and 3 AA homozygotes). Each sibling pair comprised 1 Arg188Gln GG homozygote (GG) and 1 A allele carrier (GA or AA). There were no significant differences in age, sex, or BMI between the GG and A allele carriers. In the genotype-discordant sibling-pair study, the A carriers had much higher SBP (168.29Ϯ24.67 versus 139.00Ϯ12.82 mm Hg, PϽ0.001), DBP (105.50Ϯ14.08 versus 90.75Ϯ11.07 mm Hg, Pϭ0.001), and MAP (126.33Ϯ 15.12 versus 101.92Ϯ15.69 mm Hg, PϽ0.001) than the GG homozygous siblings (Table 3) . We examined 7 families where GA heterozygotes were observed and genotypes of at least 1 parent were available and found in none of the pedigrees, the mutant allele cosegregated with hypertension.
Ethnic Comparison of the Arg188Gln
The Arg188Gln variant was identified as a heterozygous genotype in 3 of 880 French whites with essential hypertension (allele frequency, 0.17%) and was not found in 90 black Africans (online-only Data Supplement Table IV ). The 3 heterozygous hypertensive whites had no remarkable pheno-type, but their number was definitively too small to draw any valuable conclusion.
Enzymatic Activities and BP
We measured the kynureninase activity in 24 subjects from 6 hypertensive families. We found that Km was negatively correlated with SBP (rϭϪ0.500, Pϭ0.021), DBP (rϭϪ0.649, Pϭ0.001), MAP (rϭϪ0.611, Pϭ0.003), serum creatinine (rϭϪ0.478, Pϭ0.038), and serum uric acid (rϭϪ0.494, Pϭ0.032) after adjusting for age, sex, BMI, and antihypertensive medications. The negative correlation between Km and DBP remained significant after further adjustment for Arg188Gln genotype (rϭϪ0.495, Pϭ0.031).
Enzymatic Activities of Arg188Gln and Lys412Glu
In Vivo Among the 24 subjects in whom kynureninase activity was measured, we observed a significant difference of enzyme activity between Arg188Gln genotypes but not between Lys412Gln genotypes (online-only Data Supplement Table  V ). Enzyme activity of Arg188Gln A carriers was 2-fold lower than that of homozygous GG, a difference significant before and after adjusting for age, sex, BMI, MAP, and antihypertension medications (0.053Ϯ0.026 versus 0.10Ϯ0.026 mmol/L, Pϭ0.005). In contrast, there was no difference between Lys412Glu AA homozygous and G carriers (0.07Ϯ0.03 versus 0.08Ϯ0.05 mmol/L, PϾ0.05).
In Vitro
To further explain these differences, we analyzed the affinity and kinetic properties of the wild-type and mutant Arg188Gln enzymes. HEK293 cells were transiently transfected, and the expression of the recombinant KYNU/enhanced green fluorescent proteins were visualized by fluorescence microscopy. We observed significant differences of kynureninase activity between Arg188Gln variant-type and wild-type KYNU, but not for the Lys412Glu variant type and wide type ( Table 4 ). As inferred from the Vmax/Km ratio, the catalytic efficiency of Arg188Gln was less than one half of that of the wild-type KYNU enzyme (0.050Ϯ0.012 versus 0.11Ϯ0.016 mL/min per mg, Pϭ0.029).
Stable G418-resistant colonies were obtained for the Arg188Gln mutant, and the previous results were confirmed. Furthermore, the difference of Vmax/Km between Arg188Gln variant type and wild type became more evident (71.19Ϯ6.14 versus 2.79Ϯ0.090 mL/min per mg, PϽ0.001). We also looked at the location of the Arg188 and Lys412 residues as predicted by the crystal structure of Homo sapiens kynureninase. 26 Both residues are located in the large and small domain of the enzyme (Figure 2 ) within evolutionaryconversed regions along mammalian clades, suggesting that they may have functional constraints. However, protein sequence alignments across mammalian lineages indicate that Arg188 but not Lys412 were kept invariant during the mammalian evolution ( Figure 3 ).
Discussion
Kynureninase is involved in the kynurenine pathway for the biosynthesis of nicotinamide adenosine dinucleotide cofactors from tryptophan. In this study, we found that variant 188Gln increased the risk of hypertension and decrease the enzymatic activities of kynureninase.
It has been debated whether the common disease-common alleles or common disease-rare alleles determines the etiology of common complex diseases. 27 The common diseaserare alleles holds that common diseases are the result of multiple rare or low-frequency variants with large phenotypic effects and has been strongly supported by studies of several common diseases such as Crohn disease, systemic lupus erythematosus, and coronary artery disease. 28 -30 This model was also demonstrated by recent evidence that rare polymorphisms are associated with lipid level and BP variation. [31] [32] [33] In the present study, we did not find any positive association between 49 common KYNU SNPs and hypertension in the study population, although the negative results could be caused by the limited power to detect moderate effects given the small sample size. We instead considered the possibility of rare variants at the locus that could affect BP with a larger effect, and 1 missense variant, Arg188Gln, received our attention. First, Arg188 is well conserved among species because it is found in all mammalian sequences except opossum, a marsupial. Second, we found that the kinetic property of the enzyme on its natural substrate was affected by the mutant Arg188Gln. The binding site for PLP is Lys276, whereas His102 and Asn333 interact with a substrate analog bound in the active site. 26, 34, 35 Interestingly, the Arg188 residue is Ϸ25 Å away from the PLP on the surface of the large domain. It is therefore possible that this arginine-to-glutamine change might affect the interaction with the small domain to form a closed conformation when the substrate is bound.
We also found statistical evidence for an association with essential hypertension both in a case-control study and in a genotype-discordant sibling-pair study, a design that may be helpful in studies on loci with low allele frequencies. 36 The limited number of mutation carriers and large variance of BPs in the population-based cohort may lower the power to detect its effect. Indeed, we only observed a 5-mm Hg increase on the mean DBP of 47 heterozygous variant carriers compared with Ͼ2000 wild-type homozygous individuals. However, this increased susceptibility to hypertension was strongly confirmed in the 48 siblings discordant for the Arg188Gln variant, with almost a 15-mm Hg difference in DBP. Siblings share, on average, 50% of their genomes and, often, lifestyle factors influencing BP and the risk of hypertension, thus giving less weight to confounding factors. Again, even though the magnitude of the effect in the general population is probably much smaller, this compelling evidence argues strongly for a true physiological effect.
It has been recognized that kidney has a dual influence on the tryptophan metabolism. The severe disturbance in peripheral kynurenine pathway results in the decrease of plasma tryptophan level and augmentation of its metabolites in rats. 37 Recently, kynurenines were found to be associated with the markers of kidney function. 38, 39 Inflammation is a common feature of chronic kidney disease, and lines of evidence have suggested that kynurenines are associated with inflammation and oxidative status in patients with chronic kidney disease. 38, 39 In the present study, the Arg188Gln variant was associated with plasma creatinine in the case-control design but not in the discordant siblings set-up in a smaller group of individuals. Thus, it is difficult to directly link the association of hypertension with an altered kidney function. The genetic analysis of larger populations in which a full assessment of kidney function and autonomic nervous system has been investigated should help to establish a link between kynureninase activity and BP.
There were several limitations of the present study. First, in a typical quantitative trait association study of rare variants, individuals would best be sampled from the extreme tails of the trait distribution, and all subjects would have their exons sequenced. Our study, however, focused on only 1 particular variant, so it will be interesting to study whether other rare variants in the same gene affect BP-related traits. Second, although we found the Arg188Gln variant to be associated with increased BP and decreased kynureninase activity, a previous rat study 9 and our own experiments (data not shown) suggest that decreased enzymatic activities lead to higher BP. Thus, the regulatory mechanism of this variant remains to be clarified.
In summary, this study provided for the first time in our knowledge that KYNU, particularly the low-frequency variant Arg188Gln, and decreased kynureninase were associated with essential hypertension. These results were supported by in vivo and in vitro experiments. Other members of the tryptophan pathway, intermediate phenotypes, and other populations should be investigated.
